Literature DB >> 21771992

Genetics and variable drug response.

Russell A Wilke1, M Eileen Dolan.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21771992      PMCID： PMC3539154          DOI： 10.1001/jama.2011.998

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

Authors:  Mark McCormack; Ana Alfirevic; Stephane Bourgeois; John J Farrell; Dalia Kasperavičiūtė; Mary Carrington; Graeme J Sills; Tony Marson; Xiaoming Jia; Paul I W de Bakker; Krishna Chinthapalli; Mariam Molokhia; Michael R Johnson; Gerard D O'Connor; Elijah Chaila; Saud Alhusaini; Kevin V Shianna; Rodney A Radtke; Erin L Heinzen; Nicole Walley; Massimo Pandolfo; Werner Pichler; B Kevin Park; Chantal Depondt; Sanjay M Sisodiya; David B Goldstein; Panos Deloukas; Norman Delanty; Gianpiero L Cavalleri; Munir Pirmohamed
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

3.  Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

Authors:  Robert S Epstein; Thomas P Moyer; Ronald E Aubert; Dennis J O Kane; Fang Xia; Robert R Verbrugge; Brian F Gage; J Russell Teagarden
Journal:  J Am Coll Cardiol       Date:  2010-04-08       Impact factor: 24.094

4.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.

Authors:  Pei Chen; Juei-Jueng Lin; Chin-Song Lu; Cheung-Ter Ong; Peiyuan F Hsieh; Chih-Chao Yang; Chih-Ta Tai; Shey-Lin Wu; Cheng-Hsien Lu; Yung-Chu Hsu; Hsiang-Yu Yu; Long-Sun Ro; Chung-Ta Lu; Chun-Che Chu; Jing-Jane Tsai; Yu-Hsiang Su; Sheng-Hsing Lan; Sheng-Feng Sung; Shu-Yi Lin; Hui-Ping Chuang; Li-Chen Huang; Ying-Ju Chen; Pei-Joung Tsai; Hung-Ting Liao; Yu-Hsuan Lin; Chien-Hsiun Chen; Wen-Hung Chung; Shuen-Iu Hung; Jer-Yuarn Wu; Chi-Feng Chang; Luke Chen; Yuan-Tsong Chen; Chen-Yang Shen
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

5.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

6.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

Authors:  Ann K Daly; Peter T Donaldson; Pallav Bhatnagar; Yufeng Shen; Itsik Pe'er; Aris Floratos; Mark J Daly; David B Goldstein; Sally John; Matthew R Nelson; Julia Graham; B Kevin Park; John F Dillon; William Bernal; Heather J Cordell; Munir Pirmohamed; Guruprasad P Aithal; Christopher P Day
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

7.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

8.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

9.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245
  9 in total
  22 in total

Review 1.  Ethics and neuropsychiatric genetics: a review of major issues.

Authors:  Steven K Hoge; Paul S Appelbaum
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-25       Impact factor: 5.176

Review 2.  Genetic determinants of response to cardiovascular drugs.

Authors:  Quinn S Wells; Jessica T Delaney; Dan M Roden
Journal:  Curr Opin Cardiol       Date:  2012-05       Impact factor: 2.161

3.  The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Authors:  R A Wilke; L B Ramsey; S G Johnson; W D Maxwell; H L McLeod; D Voora; R M Krauss; D M Roden; Q Feng; R M Cooper-Dehoff; L Gong; T E Klein; M Wadelius; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2012-05-23       Impact factor: 6.875

Review 4.  Bioinformatics and variability in drug response: a protein structural perspective.

Authors:  Jennifer L Lahti; Grace W Tang; Emidio Capriotti; Tianyun Liu; Russ B Altman
Journal:  J R Soc Interface       Date:  2012-05-02       Impact factor: 4.118

Review 5.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.

Authors:  QiPing Feng; Russell A Wilke; Tesfaye M Baye
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

6.  Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine.

Authors:  Shaunna L Clark; Daniel E Adkins; Edwin J C G van den Oord
Journal:  Schizophr Res       Date:  2011-08-27       Impact factor: 4.939

Review 7.  Biomarkers in psychosis: an approach to early identification and individualized treatment.

Authors:  Heline Mirzakhanian; Fiza Singh; Kristin S Cadenhead
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

8.  Characterization of statin dose response in electronic medical records.

Authors:  W-Q Wei; Q Feng; L Jiang; M S Waitara; O F Iwuchukwu; D M Roden; M Jiang; H Xu; R M Krauss; J I Rotter; D A Nickerson; R L Davis; R L Berg; P L Peissig; C A McCarty; R A Wilke; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2013-10-04       Impact factor: 6.875

Review 9.  Relating human genetic variation to variation in drug responses.

Authors:  Ashraf G Madian; Heather E Wheeler; Richard Baker Jones; M Eileen Dolan
Journal:  Trends Genet       Date:  2012-07-26       Impact factor: 11.639

10.  The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Authors:  L B Ramsey; S G Johnson; K E Caudle; C E Haidar; D Voora; R A Wilke; W D Maxwell; H L McLeod; R M Krauss; D M Roden; Q Feng; R M Cooper-DeHoff; L Gong; T E Klein; M Wadelius; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2014-06-11       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.